Bayer, Orion initiate Phase III trial of ODM-201 in non-metastatic CRPC

According to a media release today from Bayer HealthCare and Orion Corporation (a Finnish pharmaceutical company), they have started to  enroll patients in a randomized Phase III clinical trial of ODM-201, a novel, oral androgen receptor inhibitor in development for the treatment of men with advanced forms of prostate cancer. … READ MORE …

“Sexual bother” in advanced prostate cancer patients on androgen deprivation therapy

“Sexual bother” is a term used in the urology literature to refer to the side effects of all sorts of different treatments as they relate to everything from sexual desire to actual erectile and sexual function, the ability to ejaculate, etc. Frankly, it is not a term we like a lot because it encompasses such a vast range of sexually problematic issues. … READ MORE …

Results of the RADAR trial at 7.4 years of follow-up

The RADAR trial (also known as TROG 03.04) was a randomized trial of 6 months of androgen deprivation therapy (ADT) + radiation therapy versus 18 months of ADT + radiotherapy, with or without additional zoledronic acid therapy, in men with intermediate- and high-risk, locally advanced prostate cancer. … READ MORE …

Early identification of androgen receptor gene amplification and prostate cancer risk

Historically, it has generally been assumed that androgen receptor gene amplification was a result of androgen deprivation therapy (ADT) and occurred in some 20 to 30 percent of men with castration-resistant prostate cancer (CRPC). However, … READ MORE …

No 15-year survival benefit associated with primary ADT in older men

In another paper just published on-line in JAMA Internal Medicine this week, the authors have provided additional data indicating — once again — the lack of any value of primary androgen deprivation therapy (ADT) in the management of early-stage, localized prostate cancer among older patients. … READ MORE …

The PATCH study will continue to accrue patients in the UK

The Prostate Adenocarcinoma: TransCutaneous Hormones or PATCH trial is an ongoing study in the UK that was designed (in a series of stages) to determine whether estrogen patch therapy might be at least no worse than (i.e., “non-inferior” to) LHRH agonist therapy in suppressing androgens to castrate level. … READ MORE …

What’s being presented at ASCO this year: II

A “first-of-its kind” quality of life study to be presented at ASCO this year is a year-long, randomized, three-arm trial of the value of “purposeful” physical exercise in the management of men on androgen deprivation therapy (ADT) for progressive prostate cancer. … READ MORE …

Follow

Get every new post delivered to your Inbox.

Join 1,151 other followers